Evidence map›Paper›PMID 34707093›Full record

ArticleCell death & disease2021

Human hepatocyte-derived extracellular vesicles attenuate the carbon tetrachloride-induced acute liver injury in mice.

Masatoshi Kakizaki, Yuichiro Yamamoto, Shunya Nakayama, Kazuaki Kameda, Etsuko Nagashima, Masatoshi Ito, Takashi Suyama, Yumi Matsuzaki, Tetsuhiro Chiba, Hideaki Sumiyoshi and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. sPLAScience advances · 2026
    Article
  3. Animal models accurately representing acute liver failure (Review).International journal of molecular medicine · 2026
    Review
  4. Extracellular Vesicle fromInternational journal of molecular sciences · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Masatoshi Kakizaki *Department of Innovative Medical Science, Tokai University School of Medicine, Kanagawa, 259-1193, Japan.
Yuichiro Yamamoto *Department of Innovative Medical Science, Tokai University School of Medicine, Kanagawa, 259-1193, Japan.
Shunya Nakayama *Department of Innovative Medical Science, Tokai University School of Medicine, Kanagawa, 259-1193, Japan.
Kazuaki KamedaDepartment of Innovative Medical Science, Tokai University School of Medicine, Kanagawa, 259-1193, Japan.
Etsuko NagashimaDepartment of Innovative Medical Science, Tokai University School of Medicine, Kanagawa, 259-1193, Japan.
Masatoshi ItoSupport Center for Medical Research and Education, Tokai University School of Medicine, Kanagawa, 259-1193, Japan.
Takashi SuyamaDepartment of Life Science, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.
Yumi MatsuzakiDepartment of Life Science, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.
Tetsuhiro ChibaDepartment of Gastroenterology, Chiba University, Graduate School of Medicine, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Hideaki SumiyoshiDepartment of Innovative Medical Science, Tokai University School of Medicine, Kanagawa, 259-1193, Japan.
Yutaka InagakiDepartment of Innovative Medical Science, Tokai University School of Medicine, Kanagawa, 259-1193, Japan.ORCID http://orcid.org/0000-0001-6640-7688
Ai KotaniDepartment of Innovative Medical Science, Tokai University School of Medicine, Kanagawa, 259-1193, Japan. aikotani@k-lab.jp.ORCID http://orcid.org/0000-0002-0976-8687
Tokai University · JPShimane University · JPChiba University · JP

Funding

Japan Agency for Medical Research and Development (AMED) 20cm0106275h0001Japan Agency for Medical Research and Development (AMED) 20fk0210054s0202MEXT | Japan Society for the Promotion of Science (JSPS) JP20H03716MEXT | Japan Society for the Promotion of Science (JSPS) JP20K21550MEXT | Japan Society for the Promotion of Science (JSPS) JPMJCR19H5MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JPMJCR19H5
6 · The paper itself

Abstract

Acute liver injury (ALI) induced by chemicals or viruses can progress rapidly to acute liver failure (ALF), often resulting in death of patients without liver transplantation. Since liver transplantation is limited due to a paucity of donors, expensive surgical costs, and severe immune rejection, novel therapies are required to treat liver injury. Extracellular vesicles (EVs) are used for cellular communication, carrying RNAs, proteins, and lipids and delivering them intercellularly after being endocytosed by target cells. Recently, it was reported that EVs secreted from human hepatocytes have an ability to modulate the immune responses; however, these roles of EVs secreted from human hepatocytes were studied only with in vitro experiments. In the present study, we evidenced that EVs secreted from human hepatocytes attenuated the CCL

Indexed as

AnimalsCarbon TetrachlorideExtracellular VesiclesFemaleHepatocytesHumansLiver Failure, AcuteMiceCarbon Tetrachloride

Identifiers

PMID34707093
PMCPMC8551237
OpenAlexW3210640338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.